Company Seeks FDA Approval for MDMA as Treatment for PTSD
By Physician’s Briefing Staff HealthDay Reporter
WEDNESDAY, Dec. 13, 2023 -- A California company is asking the U.S. Food and Drug Administration to consider approving MDMA (midomafetamine capsules) as a treatment for posttraumatic stress disorder (PTSD).
When announcing the new drug application (NDA) filing on Tuesday, MAPS Public Benefit Corp. noted it has been studying the drug for this use for years. The FDA has 60 days to decide whether MDMA will be accepted for review and whether it will be fast-tracked through the approval process, the company said. The drug would be given in concert with talk therapy.
"The filing of our NDA is the culmination of more than 30 years of clinical research, advocacy, collaboration, and dedication to bring a potential new option to adults living with PTSD, a patient group that has experienced little innovation in decades," MAPS CEO Amy Emerson said in a company news release. "If approved, MDMA-assisted therapy would be the first psychedelic-assisted therapy, which we hope will drive additional investment into new research in mental health."
Back in 2017, the FDA granted MDMA-assisted therapy a breakthrough therapy designation. The MDMA application included data on two studies, with 90 and 104 participants, respectively, that showed MDMA significantly reduced symptoms and impairment associated with PTSD when compared with a placebo. MAPS added that it has now completed a total of six late-stage clinical trials testing MDMA for PTSD.
If the FDA approves MDMA for this purpose, it would need to be rescheduled, MAPS noted, because it is a schedule I drug under the Controlled Substances Act, which the U.S. Drug Enforcement Administration defines as having no accepted medical use.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
Seven in 10 Experiencing Homelessness Have a Mental Health Disorder
WEDNESDAY, April 17, 2024 -- The majority of people experiencing homelessness have mental health disorders, according to a review published online April 17 in JAMA...
Rapid Transitions Seen From Neutral to Negative Emotional States in PTSD
WEDNESDAY, April 17, 2024 -- Individuals with posttraumatic stress disorder (PTSD) undergo rapid transitions between neutral and negative emotional states, which are intensified...
Text-Embedding Model Can Identify PTSD Following Childbirth
TUESDAY, April 16, 2024 -- A text-embedding-ada-002 (ADA) machine learning model can identify posttraumatic stress disorder following childbirth (CB-PTSD) from maternal childbirth...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.